Genetic “Trojan horse” selectively kills cancer cells linked to Kaposi’s sarcoma, UC Davis study shows

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

In a preclinical study, UC Davis Comprehensive Cancer Center scientists developed a highly targeted gene therapy that could revolutionize treatment for cancers linked to a common herpesvirus, with minimal side effects.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

Cell and gene therapies are steadily becoming more available to patients, but are still facing systemic hurdles slowing widespread adoption, according to the second annual 2025 “Cell and Gene Therapy Report: Advancing the Future of Medicine,” published by InspiroGene by McKesson. The report draws on new insights from research with physicians and payers, an updated...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login